https://scholars.lib.ntu.edu.tw/handle/123456789/558565
標題: | Metronomic chemotherapy with tegafur-uracil following radical resection in stage II colorectal cancer | 作者: | TZU-CHUN CHEN YUNG-MING JENG JIN-TUNG LIANG |
公開日期: | 2021 | 出版社: | Elsevier B.V. | 卷: | 120 | 期: | 5 | 起(迄)頁: | 1194-1201 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Background: Stage II colorectal cancer has a relatively good prognosis. Adjuvant chemotherapy following surgery is the standard treatment for stage III colorectal cancer but is not routinely recommended for all stage II colorectal cancer patients. We aimed to evaluate the clinical outcomes, treatment results, and prognostic factors in stage II colorectal cancer patients who underwent curative surgery with/without oral tegafur-uracil (UFT). Methods: We included stage II colorectal cancer patients who underwent curative surgery and were followed up for at least 5 years after surgery at the National Taiwan University Hospital between January 2008 and December 2012. Excluding patients receiving neoadjuvant therapy, adjuvant therapy other than UFT, and those lost follow-up, patients treated with UFT (UFT group) and those without adjuvant therapy (surgery alone group) were analyzed for their clinical outcomes and prognostic factors. Results: A total of 233 patients were recruited. Of these, 104 (44.64%) underwent only surgery while 129 (55.36%) received adjuvant chemotherapy with oral UFT following surgery. Recurrence or death occurred within 5 years in 60 patients (25.75%), with a significant difference between the surgery alone (36/104, 34.62%) and UFT groups (24/129, 18.61%) (p = 0.007). The UFT group demonstrated significantly superior 5-year disease-free (p = 0.003) and overall survival rates (p = 0.001), respectively. Patient age of ?35.3 or ?72.7 years, UFT duration of <486.8 days, 7.1 cm < tumor size ?13.2 cm, number of harvested lymph nodes ?13.5, and mucinous adenocarcinoma were associated with poorer 5-year overall survival. Conclusion: The present data suggest that UFT following curative surgery may be associated with lower recurrence and improved survival in patients with stage II colorectal cancer. ? 2020 Formosan Medical Association |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092180124&doi=10.1016%2fj.jfma.2020.09.014&partnerID=40&md5=3334893b33d85b88d33b719f4c1b5c88 https://scholars.lib.ntu.edu.tw/handle/123456789/558565 |
ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2020.09.014 | SDG/關鍵字: | folic acid; folinate calcium; UFT; ufur; antineoplastic agent; tegafur; uracil; adjuvant therapy; adult; aged; Article; cancer chemotherapy; cancer patient; cancer prognosis; cancer recurrence; cancer staging; clinical outcome; colloid carcinoma; colorectal cancer; controlled study; death; demography; disease free survival; evaluation study; female; follow up; human; lymph node; major clinical study; male; neoadjuvant therapy; overall survival; radical resection; regression analysis; Taiwan; tumor volume; university hospital; adjuvant chemotherapy; cancer staging; colorectal tumor; pathology; tumor recurrence; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Taiwan; Tegafur; Uracil |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。